1
|
Canioni D, Brice P, Bologna S, Voillat L, Gabarre J, Casasnovas O, Devidas A, Coiffier B, Aoudjhane A, Audouy B, Andre M, Fortpied C, Carde P, Mounier N, Briere J. PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN STAGE III/IV CLASSICAL HODGKIN LYMPHOMA TREATED FRONTLINE IN THE LYSA EORTC 20012 RANDOMIZED PROTOCOL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- D. Canioni
- Pathology Department; Hopital Necker; Paris France
| | - P. Brice
- Hematology Department; Hopital Saint-Louis; France
| | - S. Bologna
- Meurte-Moselle; Centre d'Oncologie de Gentilly, Essey-les Nancy; France
| | - L. Voillat
- Hematology Department; Centre Hospitalier de Chalon sur Saône, Chalon sur Saone; France
| | - J. Gabarre
- Hematology Department; Hopital Pitié-Salpétrière; France
| | | | - A. Devidas
- Hematology Department; CH de Corbeil-Essones; Corbeil- Essones France
| | - B. Coiffier
- Hematology Department; Hospices Civils de Lyon; Pierre Bénite France
| | - A. Aoudjhane
- Hematology Department; Hopital Saint-Antoine; France
| | - B. Audouy
- Hematology Department; CH de Colmar; Colmar France
| | - M. Andre
- Hematology Department; CH de Mont Godinne; Yvoir Belgium
| | | | - P. Carde
- Hematology Department; Hopital Américain, Neuillyè-sur-Seine; France
| | - N. Mounier
- Hematology Department; Hopital de l'Archet; Nice France
| | - J. Briere
- Pathology Department; Hopital Necker; Paris France
| |
Collapse
|
2
|
Ghez D, Fortpied C, Mounier N, Carde P, Perrot A, Khaled H, Amorim S, Ramadan S, Bras FL, Erlanson M, Herbaux C, Marolleau JP, Nicolas-Virelezier E, Casasnovas O, Stamatoullas-Bastard A, Fermé C. First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma. Bone Marrow Transplant 2016; 52:310-312. [PMID: 27892946 DOI: 10.1038/bmt.2016.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- D Ghez
- Department of Hematology, Gustave Roussy, Villejuif, France
| | | | - N Mounier
- Department of Onco-Hematology, CHU l'Archet, Nice, France
| | - P Carde
- Department of Hematology, Gustave Roussy, Villejuif, France
| | - A Perrot
- Department of Hematology, CHU Nancy-Brabois, Vandoeuvre Les Nancy, France
| | - H Khaled
- Department of Medical Oncology, National Cancer Institute, Cairo, Egypt
| | - S Amorim
- Department of Oncology and Hematology, Hopital Saint-Louis APHP, Université Paris Diderot, Paris, France
| | - S Ramadan
- EORTC Headquarters, Brussels, Belgium
| | - F L Bras
- Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor, Creteil, France
| | - M Erlanson
- Department of Oncology, Umea Universitet, Umea, Sweden
| | - C Herbaux
- Department of Clinical Hematology, Hôpital Claude Huriez, Université de Lille 2, Lille, France
| | - J-P Marolleau
- Department of Hematology, CHU Amiens, Université Picardie Jules Verne, Amiens, France
| | | | - O Casasnovas
- Department of Hematology, CHU Dijon, Dijon, France
| | | | - C Fermé
- Department of Hematology, Gustave Roussy, Villejuif, France
| |
Collapse
|
3
|
M'kacher R, Girinsky T, Colicchio B, Ricoul M, Dieterlen A, Jeandidier E, Heidingsfelder L, Cuceu C, Shim G, Frenzel M, Lenain A, Morat L, Bourhis J, Hempel WM, Koscielny S, Paul JF, Carde P, Sabatier L. Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposure. Radiat Prot Dosimetry 2015; 164:134-137. [PMID: 25274533 DOI: 10.1093/rpd/ncu296] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Telomere length has been proposed as a marker of mitotic cell age and as a general index of human organism aging. Telomere shortening in peripheral blood lymphocytes has been linked to cardiovascular-related morbidity and mortality. The authors investigated the potential correlation of conventional risk factors, radiation dose and telomere shortening with the development of coronary artery disease (CAD) following radiation therapy in a large cohort of Hodgkin lymphoma (HL) patients. Multivariate analysis demonstrated that hypertension and telomere length were the only independent risk factors. This is the first study in a large cohort of patients that demonstrates significant telomere shortening in patients treated by radiation therapy who developed cardiovascular disease. Telomere length appears to be an independent prognostic factor that could help determine patients at high risk of developing CAD after exposure in order to implement early detection and prevention.
Collapse
Affiliation(s)
- R M'kacher
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France Laboratory of Radiation Sensitivity and Radio-carcinogenesis INSERM 1030, Institut Gustave Roussy, Villejuif 94 804, France
| | - T Girinsky
- Department of Radiation Oncology, Institut Gustave Roussy, Villejuif 94 804, France
| | - B Colicchio
- Laboratoire MIPS - Groupe TIIM3D, Université de Haute-Alsace, Mulhouse Cedex F-68093, France
| | - M Ricoul
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - A Dieterlen
- Laboratoire MIPS - Groupe TIIM3D, Université de Haute-Alsace, Mulhouse Cedex F-68093, France
| | - E Jeandidier
- Department of genetics, CHU, Mulhouse Cedex 68093, France
| | - L Heidingsfelder
- MetaSystems GmbH, Robert-Bosch-Str. 6, Altlussheim D-68804, Germany
| | - C Cuceu
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - G Shim
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - M Frenzel
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France Laboratory of Radiation Sensitivity and Radio-carcinogenesis INSERM 1030, Institut Gustave Roussy, Villejuif 94 804, France Department of Radiation Oncology, Institut Gustave Roussy, Villejuif 94 804, France Laboratoire MIPS - Groupe TIIM3D, Université de Haute-Alsace, Mulhouse Cedex F-68093, France Department of genetics, CHU, Mulhouse Cedex 68093, France MetaSystems GmbH, Robert-Bosch-Str. 6, Altlussheim D-68804, Germany Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif 94 804, France Department of Radiology, Marie Lannelongue, Chatenay-Malabry 92019, France Department of hematology, Institut Gustave Roussy, Villejuif 94 804, France
| | - A Lenain
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - L Morat
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - J Bourhis
- Laboratory of Radiation Sensitivity and Radio-carcinogenesis INSERM 1030, Institut Gustave Roussy, Villejuif 94 804, France Department of Radiation Oncology, Institut Gustave Roussy, Villejuif 94 804, France Laboratoire MIPS - Groupe TIIM3D, Université de Haute-Alsace, Mulhouse Cedex F-68093, France Department of genetics, CHU, Mulhouse Cedex 68093, France
| | - W M Hempel
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - S Koscielny
- Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif 94 804, France
| | - J F Paul
- Department of Radiology, Marie Lannelongue, Chatenay-Malabry 92019, France
| | - P Carde
- Department of hematology, Institut Gustave Roussy, Villejuif 94 804, France
| | - L Sabatier
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| |
Collapse
|
4
|
Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M, Gabarre J, Casasnovas O, Jaubert J, Colin P, Delmer A, Devidas A, Bachy E, Nicolas-Virelizier E, Aoudjhane A, Humbrecht C, Andre M, Carde P. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial. Ann Oncol 2014; 25:1622-8. [DOI: 10.1093/annonc/mdu189] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Pedergnana V, Syx L, Cobat A, Guergnon J, Brice P, Ferme C, Carde P, Hermine O, Le Pendeven C, Amiel C, Theodorou I, Abel L, Besson C. Combined Linkage and Association Studies of Antibodies against EBV Antigens Confirm the Role of HLA Class II Variants in the Control of Anti-EBNA1 IgG Levels and in the Risk of Hodgkin's Lymphoma. Klin Padiatr 2014. [DOI: 10.1055/s-0034-1371107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
6
|
Meijnders P, Carde P, Girinsky T, Kluin-Nelemans J, Henry-Amar M, Raemaekers J, Karrasch M, van der Maazen R. Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy. EJC Suppl 2012. [DOI: 10.1016/s1359-6349(12)70019-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
M’kacher R, Andreoletti L, Flamant S, Milliat F, Girinsky T, Dossou J, Violot D, Assaf E, Clausse B, Koscielny S, Bourhis J, Bosq J, Bernheim A, Parmentier C, Carde P. JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin’s lymphoma patients and poor clinical outcome. Ann Oncol 2010; 21:826-832. [DOI: 10.1093/annonc/mdp375] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V. Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation. Leuk Lymphoma 2008; 46:861-7. [PMID: 16019530 DOI: 10.1080/10428190500054350] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
High-dose therapy (HDT) is now recommended for patients under 60 years of age with chemosensitive relapsed aggressive non-Hodgkin's lymphoma. However, approximately half of these patients will be cured by HDT. Prognostic factors are needed to predict which patients with chemosensitive lymphoma to second-line therapy could benefit from HDT. We retrospectively investigated the prognostic value of the widely used age-adjusted International Prognostic Index (AA-IPI) calculated at the time of relapse (35 patients) or just before second-line salvage therapy for primary refractory disease (5 patients). The median age was 51 years (range 18-64 years). Thirty-six patients had diffuse large B-cell lymphoma. Salvage cytoreductive therapy before HDT was DHAP/ESHAP (cytarabine, cysplatin, etoposide, steroids) in 17 patients, VIM3-Ara-c/MAMI (high-dose cytarabine, ifosfamide, methyl-gag, amsacrine) in 17 patients, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or reinforced CHOP in 4 patients, high-dose cyclophosphamide and etoposide in 2 patients. The HDT regimen consisted of BEAM (carmusine, cytarabine, etoposide, melphalan) in all cases. Eleven patients were in partial remission and 29 in complete remission at the time of HDT. Ten patients had an IPI >1, 16 had relapsed early (<6 months after first-line therapy) or disease was refractory to first-line therapy (5 of the 16 patients). The median follow-up was 6.07 years (range 1.24-9.74 years). Overall survival was not statistically different in patients with refractory disease or in those who relapsed early compared with late failures (>6 months after first-line chemotherapy) (P=1), but the AA-IPI >1 was associated with a poor outcome (P=0.03). In conclusion, the AA-IPI could have a prognostic value in patients with chemosensitive recurrent lymphoma treated with BEAM HDT.
Collapse
Affiliation(s)
- E Jabbour
- Département de Médecine, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
|
10
|
Carde P. OP32 Late effects in survivors of Hodgkin's lymphoma. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70312-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Validire P, Fermé C, Brice P, Diviné M, Gabarre J, Bouabdallah K, Fitoussi O, Chaoui D, Soussain C, Carde P, Decaudin D. A large multicentric study of gemcitabine-based regimen in relapsed or refractory Hodgkin lymphoma (HL) patients (pts). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18518 Background: The aim of this study was to assess the efficacy and safety of gemcitabine-based regimen in heavily pretreated HL pts. Methods: Relapsed or refractory HL pts treated with gemcitabine were retrospectively reviewed. Gemcitabine was used as a single agent or administered in combination with vinorelbine, oxaliplatine, doxorubicine, vinblastine, rituximab, and/or corticosteroids. Results: Fifty-five pts treated in 9 departments of clinical hematology between January 1999 and August 2006 were included in the study. Initial characteristics before gemcitabine administration were: nodular sclerosis in 84%; sex ratio M/F 1.1; median age 29 years (range: 15–85 years); advanced stage 84%; extranodal sites were lung, bone, liver, soft tissues, and bone marrow in 68%, 31%, 13%, 21%, and 4%, respectively; Hasenclever index lower than 3 in 20/43 cases (47%). At the end of the first front-line therapy (chemotherapy ± radiotherapy), 19 pts (35%) were in complete response (CR) in whom 13 relapsed within one year, 5 were in partial response (PR), and 31 pts were primary refractory (56%). Median number of previous chemotherapeutic regimen was 3 (range 1–8), 39 pts (71%) have received radiotherapy (RT), and 34 pts (62%) one or two autologous/allogenic stem cell transplantations (A/ASCT). Twenty-nine pts received gemcitabine alone with a median initial dose per injection of 750 mg/m2 (range: 180–1250 mg/m2); Gemcitabine was administered at an initial dose per injection of 1000 mg/m2 (range: 500–1250) in combination with vinorelbine in 10 pts, oxaliplatine in 13 pts in whom 4 with rituximab, and with others drugs in 3 pts. In both cases, the median number of combined gemcitabine regimen injections was 6 (range: 1–27). Toxicity was mainly hematological (75% of pts developed bi- or pancytopenia) or infectious (13%). Among all included pts, 6 were in CR (11%) and 5 in PR with an overall response rate of 20%. Among the 6 CR, 5 pts received thereafter A/ASCT and 2 pts RT, with 2 persistent CR at 16 and 44 months. In univariate analysis, none prognostic factor for response to gemcitabine was identified. Conclusions: This study, which constitutes one of the most important series, showed a mild efficacy of gemcitabine-based regimen in heavily pretreated HL patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Validire
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - C. Fermé
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - P. Brice
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - M. Diviné
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - J. Gabarre
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - K. Bouabdallah
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - O. Fitoussi
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - D. Chaoui
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - C. Soussain
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - P. Carde
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| | - D. Decaudin
- Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Hôpital Saint-Louis, Paris, France; Hôpital Henri Mondor, Créteil, France; Hôpital de la Pitié Salpétrière, Paris, France; Hôpital haut l’Evêque, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Victor Dupouy, Argenteuil, France; Centre Rene Huguenin, Saint Cloud, France
| |
Collapse
|
12
|
Carde P, Andreoletti L, Koscielny S, Assaf E, Girinsky T, Bosq J, Bernheim A, Flamant S, Violot D, Parmentier C, M’Kacher R. JC human polyomavirus (JCV) and Epstein-Barr virus (EBV) replicative activities are detected in Hodgkin/Reed Sternberg cells (HRS) and circulating lymphocytes (PBL) of Hodgkin lymphoma (HL) and associated with relapse, especially in younger patients. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7551] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7551 Background: The HRS derive from germinal-center B-cells, potential sites for latency and reactivation of JCV in immunosuppressed individuals. Replication of human polyomaviruses (JC, BK, SV40) and EBV was assessed in Hodgkin (HL) and B cell non-Hodgkin (B-NHL) lymphomas. Methods: FISH, immunohistochemistry for oncogenic proteins, PCR and DNA sequencing to identify polyomaviruses and EBV on involved nodes and in PBL before, during and after treatment (N = 73 HL, 91 B-NHL). Controls were 30 healthy donors, 70 solid tumors and 14 acute leukemia patients. Results: using FISH, JCV and EBV DNA were detected in all lymphoma nodes. High genome copy number of JCV and EBV were present in 60% and 63%, respectively, in HL patients versus 11% and 14% in B-NHL patients (P < 10−6; P < 10−5). Using nest-PCR, JCV DNA sequencing after laser capture microdissection identified the presence and specificity of JCV sequences in HRS. T antigen and LMP1 co-expression, in 34% of HRS, was associated with early HL relapse (P < 10−4), particularly in young patients (P < 10−5). Only in HL patients PBL, genome copy number of JCV increased significantly during treatment (42%). Rogue cells (cultured lymphocytes with multiple complex chromosomal aberrations indicative of genomic instability) appeared in 40% of patients, and correlated with relapse (p < 10−4). The same JCV sequences were found in tumor cells and PBL of HL patients. Co-genomic replication of EBV and JCV was highly correlated in lymph nodes and in PBL in HL. Conclusions: JCV genomic replication was detected for the first time in HRS, and associated to rogue cell emergence in PBL. Co-detections of JCV and EBV genomic replication in HRS and PBL are associated with relapse, especially in young patients. HRS and PBL JCV/EBV infections are linked and worth further studies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Carde
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - L. Andreoletti
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - S. Koscielny
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - E. Assaf
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - T. Girinsky
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - J. Bosq
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - A. Bernheim
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - S. Flamant
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - D. Violot
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - C. Parmentier
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| | - R. M’Kacher
- Institut Gustave Roussy, Villejuif, France; Robert Debre Hospital, Reims, France
| |
Collapse
|
13
|
Noordijk EM, Thomas J, Fermé C, van ’t Veer MB, Brice P, Diviné M, Morschhauser F, Carde P, Eghbali H, Henry-Amar M. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6505] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. M. Noordijk
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - J. Thomas
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - C. Fermé
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - M. B. van ’t Veer
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - P. Brice
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - M. Diviné
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - F. Morschhauser
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - P. Carde
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - H. Eghbali
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| | - M. Henry-Amar
- Leiden Univ Medcl Ctr, Leiden, The Netherlands; Univ Hosp Gasthuisberg, Leuven, Belgium; Inst Gustave Roussy, Villejuif, France; Erasmus Medcl Ctr, Rotterdam, The Netherlands; Hosp Saint-Louis, Paris, France; Hosp Henri Mondor, Creteil, France; Ctr Hospitalier Univ, Lille, France; Inst Bergonié, Bordeaux, France; Ctr Régional Francois Baclesse, Caen, France
| |
Collapse
|
14
|
Jabbour E, Chalhoub B, Suzan F, Aloulou S, Cainap C, Toumi N, Fermé C, Carde P, Ribrag V. Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk Lymphoma 2004; 45:1391-4. [PMID: 15359638 DOI: 10.1080/10428190310001653736] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
We retrospectively evaluated the outcome of 94 consecutive elderly patients treated at our center for an aggressive lymphoma without a low-grade component. Median survival was 26 months and 5-year overall survival was 39% (27-50%). We then evaluated the outcome of patients refractory to or relapsing after CHOP or CHOP-like chemotherapy. Twenty patients were refractory to first-line therapy and only 1/20 is alive with active lymphoma. Eight patients achieved a partial response and only 3 maintained the partial response while the other 5 patients died. Only 2 of the 27 patients who relapsed after a first complete remission achieved a second sustained complete remission. This study suggests that conventional-dose second-line chemotherapy yields disappointing results in elderly patients with aggressive lymphomas.
Collapse
Affiliation(s)
- E Jabbour
- Département de Médecine: Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Ribrag V, Koscielny S, Vantelon JM, Fermé C, Rideller K, Carde P, Bourhis JH, Munck JN. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas. Leuk Lymphoma 2004; 44:1529-33. [PMID: 14565655 DOI: 10.3109/10428190309178775] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
UNLABELLED CPT11, a camptothecin analogue, is a specific DNA topoisomerase I inhibitor, with activity in tumor cell lines with MDR expression. CPT11 has a broad spectrum of activity in solid tumors (especially in colorectal, gastric and small cell lung cancers). Early reports have shown that CPT11 could be active in non-Hodgkin's lymphomas (NHL) with low-dose schedules. To further evaluate the efficacy and toxicity of CPT11 in patients with refractory or relapsed NHLs, we conducted a phase II trial with escalated doses. PATIENTS AND THERAPY From 04/98 to 05/01, 28 patients with NHL were enrolled. PATIENTS CHARACTERISTICS M/F 21/7; median age: 56 years (range 28-72); Ann Arbor stage at the time of the study I/II and III/IV in 6 and 21 patients, respectively. Sixteen patients had refractory disease when they were enrolled in this phase II study and 8 patients were previously treated with high-dose therapy and stem-cell transplantation. CPT11 was administrated at the doses of 350 mg/m2 every 3 weeks. Six courses were given in patients who achieved CR, PR or stable disease. Patients were evaluated every 2 courses. If no grade II or more toxicity was observed after the first course, escalated dose (500 mg/m2) was then undertaken. RESULTS 19/28 patients received more than 2 courses of CPT11 and were evaluated for response. Nine patients received one course of therapy because of either progressive disease (n = 6), toxicity (n = 2) or refusal (n = 1). Ten patients received escalated dose (500 mg/m2). Complete remission and partial was achieved in 2/19 patients, stable disease in 7/19, and progressive disease in 10/19 patients. Median duration of responses was short (3 months, range 1-8 months). Seventy-five courses were evaluated for toxicity according to the WHO criteria. Diarrhea grade 2 or 3 occurred in 9/75 courses; cholinergic syndrome grade 2 in 3/75 courses; nausea grade 3 in 7/75 courses. Hematological toxicity: leucopenia grade 3 or 4 in 21/75 courses; thrombocytopenia grade 3 in 8/75 courses; infectious episodes grade 2 or 3 in 7/75 courses. In 2/7 courses with escalated doses, grade I/IV neutropenia occurred withoutother major toxicity. CONCLUSION CPT11 has low activity in heavily pretreated NHLs. Responses were of short duration.
Collapse
Affiliation(s)
- V Ribrag
- Department de Médecine, Institut Gustave-Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Moser EC, Noordijk EM, van Glabbeke M, Teodorovic I, de Wolf-Peeters C, Carde P, Baars JW, Tirelli U, Raemaekers JMM, Kluin-Nelemans JC. Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin’s lymphoma in three randomised EORTC trials. Eur J Cancer 2004; 40:474-80. [PMID: 14962711 DOI: 10.1016/j.ejca.2003.11.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2003] [Revised: 09/30/2003] [Accepted: 11/04/2003] [Indexed: 10/26/2022]
Abstract
We analysed data from 936 newly-diagnosed patients with advanced, aggressive non-Hodgkin's lymphoma (NHL) treated in three randomised European Organisation for Research and Treatment of Cancer (EORTC) trials performed between 1980 and 1999 (median follow-up of 8.7 (0.2-20.4) years). The CHOP-like regimen CHVmP/BV (cyclophosphamide, doxorubicin, teniposide and prednisone with bleomycin and vincristine at mid-interval), was compared with CHVmP (CHVmP/BV without bleomycin and vincristine), ProMACE-MOPP (methotrexate, doxorubicin, cyclophosphamide, etoposide, mechlorethamide, vincristine, procarbazine and prednisone) and CHVmp/BV with additional, autologous stem-cell transplantation, respectively. Overall, treatment with CHVmP/BV resulted in a better long-term outcome with 63% complete responses being observed and an overall survival (OS) of 59 and 43% at 5 and 10 years, respectively. Remarkably, OS after CHVmP/BV improved across the trials, even after stratifying for the International Prognostic Index (IPI). This finding could not be directly related to better salvage treatments during the last decade. Selection bias appears to be responsible: stepwise corrections for small differences in inclusion criteria eliminated the difference in OS, especially when histological subgroups were studied. This systemic review underlines the difficulties encountered in retrospective sub-set analyses and the biases that can be introduced when recent studies are compared with older ones.
Collapse
Affiliation(s)
- E C Moser
- Department of Radiotherapy, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC Leiden, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
M'kacher R, Girinsky T, Koscielny S, Dossou J, Violot D, Béron-Gaillard N, Ribrag V, Bourhis J, Bernheim A, Parmentier C, Carde P. Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients. Int J Radiat Oncol Biol Phys 2003; 57:321-6. [PMID: 12957241 DOI: 10.1016/s0360-3016(03)00578-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
PURPOSE To study chromosomal abnormalities in 49 patients with Hodgkin's lymphoma (HL), before and after treatment and at several times during a 2-year period. METHODS AND MATERIALS Simple chromosomal aberrations (CAs) and complex chromosomal rearrangements (CCRs) were counted in peripheral lymphocytes by painting of chromosomes 1, 3, and 4 (fluorescence in situ hybridization). A control population was composed of 20 healthy donors and 69 untreated cancer patients who had undergone various radiologic scans. RESULTS A greater frequency (p < 10(-4)) of spontaneous cytogenetic abnormalities was observed in untreated HL patients compared with the control populations. CCRs were observed exclusively in the HL population (p < 10(-4)). Chemotherapy was associated with a significant increase in the frequency of CAs (p < 10(-4)), according to the chemotherapy regimen (p = 0.002). Immediately after radiotherapy, a significant increase (p < 10(-4)) was observed in CAs according to the size of the irradiation field. Conversely, the significant increases in the frequency of CCRs observed after treatment did not correlate with the chemotherapy regimens, radiotherapy dose, or size of the irradiation field. The evolution of CAs vs. CCRs over time was also dissociated: during the follow-up of these patients, a significant decrease was observed in the frequency of CAs at 6 months and 1 and 2 years. In contrast, after an initial decrease for up to 6 months after treatment, the frequency of CCRs remained constant for up to 2 years. CONCLUSION Increased cytogenetic abnormalities were observed in untreated HL patients compared with the control populations. The greater frequency of cytogenetic abnormalities persisted in some patients. The presence of CCRs supports the concept of a unique genetic environment in HL patients that persists in response to potentially noxious treatments.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Case-Control Studies
- Chromosome Aberrations
- Chromosome Painting
- Chromosomes, Human, Pair 1/genetics
- Chromosomes, Human, Pair 1/radiation effects
- Chromosomes, Human, Pair 3/genetics
- Chromosomes, Human, Pair 3/radiation effects
- Chromosomes, Human, Pair 4/genetics
- Chromosomes, Human, Pair 4/radiation effects
- Female
- Hodgkin Disease/drug therapy
- Hodgkin Disease/genetics
- Hodgkin Disease/radiotherapy
- Humans
- Lymphocytes/radiation effects
- Male
- Middle Aged
- Statistics, Nonparametric
Collapse
Affiliation(s)
- R M'kacher
- Department of Medicine, Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
M'kacher R, Bennaceur A, Farace F, Laugé A, Plassa LF, Wittmer E, Dossou J, Violot D, Deutsch E, Bourhis J, Stoppa-Lyonnet D, Ribrag V, Carde P, Parmentier C, Bernheim A, Turhan AG. Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene 2003; 22:7905-12. [PMID: 12970738 DOI: 10.1038/sj.onc.1206826] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Mantle cell lymphomas (MCL) are characterized by their aggressive behavior and poor response to chemotherapy regimens. We report here evidence of increased in vitro radiation sensitivity in two cell lines that we have generated from two MCL patients (UPN1 and UPN2). However, despite their increased radiation sensitivity, UPN2 cells were totally resistant to apoptotic cell death, whereas UPN1 cells underwent massive apoptosis 6 h after irradiation. The frequency of induced chromosomal abnormalities was higher in UPN1 as compared to UPN2. Distinct mechanisms have been found to contribute to this phenotype: a major telomere shortening (UPN1 and UPN2), deletion of one ATM allele and a point mutation in the remaining allele in UPN2, mutation of p53 gene (UPN1 and UPN2) with absence of functional p53 as revealed by functional yeast assays. After irradiation, Ku70 levels in UPN1 increased and decreased in UPN2, whereas in the same conditions, DNA-PKcs protein levels decreased in UPN1 and remained unchanged in UPN2. Thus, irradiation-induced apoptotic cell death can occur despite the nonfunctional status of p53 (UPN1), suggesting activation of a unique pathway in MCL cells for the induction of this event. Overall, our study demonstrates that MCL cells show increased radiation sensitivity, which can be the result of distinct molecular events. These findings could clinically be exploited to increase the dismal response rates of MCL patients to the current chemotherapy regimens.
Collapse
Affiliation(s)
- R M'kacher
- Department of Medicine, UPRES EA 27-10, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
M'kacher R, Farace F, Bennaceur-Griscelli A, Violot D, Clausse B, Dossou J, Valent A, Parmentier C, Ribrag V, Bosq J, Carde P, Turhan AG, Bernheim A. Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model. Cancer Genet Cytogenet 2003; 143:32-8. [PMID: 12742154 DOI: 10.1016/s0165-4608(02)00823-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32), which is associated with cyclin D1 hyperexpression and a poor prognosis. MCL cases have been shown to progress to a more aggressive disease but the molecular events responsible of this phenomenon have not been determined. We have established two cell lines from the pleural effusions of two patients with MCL that we have used for further cytogenetic characterization to better define the incidence and nature of secondary chromosome abnormalities using multicolor fluorescence in situ hybridization, whole chromosome paint, and specific probes. Both cell lines grew independently without growth factors. Using CCND1/IGH-specific probes, patient UPN1 was found to have a masked t(11;14). Numerous and complex chromosomal abnormalities were found in both cell lines affecting chromosomes 2, 8, 13, 18, 22, X, and Y. These abnormalities included 8p losses, suggesting the presence of an anti-oncogene in this region, rearrangements of 8q24, MYC gene, and translocations involving 8, X, and Y chromosomes, which might be significant in the pathogenesis of MCL progression. The use of the cell lines (UPN1) allowed us to generate a mouse model of human MCL, mimicking a disseminated lymphoma and leading to the death of the animals in 4 weeks. This blastoid MCL model could be of major interest to determine molecular events involved in MCL progression, allowing isolation of involved genes and their functional characterization, and to study the effects of new chemotherapy regimens in mouse models.
Collapse
MESH Headings
- Animals
- Chromosome Aberrations
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 14
- Disease Models, Animal
- Humans
- In Situ Hybridization, Fluorescence
- Lymphoma, Mantle-Cell/genetics
- Male
- Mice
- Mice, Inbred NOD
- Mice, SCID
- Middle Aged
- Neoplasm Transplantation
- Translocation, Genetic
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- R M'kacher
- Departments of Medicine, Pathology and Clinical Biology, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
M'kacher R, Violot D, Aubert B, Girinsky T, Dossou J, Béron-Gaillard N, Carde P, Parmentier C. Premature chromosome condensation associated with fluorescence in situ hybridisation detects cytogenetic abnormalities after a CT scan: evaluaton of the low-dose effect. Radiat Prot Dosimetry 2003; 103:35-40. [PMID: 12596987 DOI: 10.1093/oxfordjournals.rpd.a006112] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
The purpose of this study was to assess the cytogenetic effects of the X ray irradiation used during a CT scan in order to estimate the mean absorbed dose in circulating lymphocytes. Chromosomal aberrations were scored in blood lymphocytes of ten patients undergoing CT scans, by applying fluorescence in situ hybridisation (FISH) to metaphase cells and premature chromosome condensation (PCC) with chromosomes 1, 3 and 4 painting probes immediately after exposure. This generated a dosimetric index that reflects the dose to the circulating lymphocytes. By using PCC a significant increase in the frequency of chromosomal fragment was observed immediately after a CT scan. However, no significant increase in chromosomal aberration was detected in metaphase cells. The mean dosimetric index immediately after exposure was 0.057 Gy (95% CI: 0.052-0.082 Gy). This dosimetric index depends essentially on the size of the examined and exposed blood volumes. This dose is in close agreement with the dose length product (DLP) (Gy cm) (R = 0.80). It should be kept in mind when justifying requests for diagnostic CT scan especially in young patients. The presence of chromosomal fragments after a CT scan indicated the cytogenetic effect of a low dose. PCC associated with chromosome painting is a method for detecting the cytogenetic effect of a low dose immediately after exposure.
Collapse
MESH Headings
- Adult
- Animals
- Blood/radiation effects
- CHO Cells/radiation effects
- Carcinoma/diagnostic imaging
- Chromosome Aberrations
- Chromosome Breakage
- Chromosome Painting
- Chromosomes/radiation effects
- Chromosomes, Human/radiation effects
- Chromosomes, Human, Pair 1/radiation effects
- Chromosomes, Human, Pair 1/ultrastructure
- Chromosomes, Human, Pair 3/radiation effects
- Chromosomes, Human, Pair 3/ultrastructure
- Chromosomes, Human, Pair 4/radiation effects
- Chromosomes, Human, Pair 4/ultrastructure
- Cricetinae
- Cricetulus
- Dose-Response Relationship, Radiation
- Female
- Head and Neck Neoplasms/diagnostic imaging
- Humans
- Interphase
- Lymphocytes/radiation effects
- Lymphocytes/ultrastructure
- Male
- Metaphase
- Middle Aged
- Mitosis/radiation effects
- Phantoms, Imaging
- Radiometry/instrumentation
- Thyroid Neoplasms/diagnostic imaging
- Tomography, X-Ray Computed/adverse effects
- Translocation, Genetic
- Urologic Neoplasms/diagnostic imaging
Collapse
Affiliation(s)
- R M'kacher
- Department of Medicine, UPRES EA 27-10 Institut Gustave Roussy, 94805 Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Ribrag V, Koscielny S, Vantelon J, Fermé C, Rideller K, Carde P, Bourhis J, Munck J. Phase II Trial of Irinotecan (CPT-11) in Relapsed or Refractory Non-Hodgkin's Lymphomas. Leuk Lymphoma 2003. [DOI: 10.1080/1042819031000099643] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
Carde P, Koscielny S, Franklin J, Axdorph U, Raemaekers J, Diehl V, Aleman B, Brosteanu O, Hasenclever D, Oberlin O, Bonvin N, Björkholm M. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol 2002; 13 Suppl 1:86-91. [PMID: 12078910 DOI: 10.1093/annonc/13.s1.86] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Early adjustment of treatment may benefit the patient. In order to guide treatment adjustment, use of early response (ER) or early complete response (ECR), judged after the few initial cycles of chemotherapy, is common in pediatric and also adult Hodgkin's and non-Hodgkin's studies. Paradoxically, almost no data support this strategy. PATIENTS AND METHODS The influence of ECR on outcome was evaluated in three series of advanced Hodgkin's disease (HD), leading to a series of questions. RESULTS The 1982 EORTC study assessed prospectively the time frame needed to reach an apparent complete response (CR) through repeated tumor measurements. In patients assessed at mid-treatment before the fifth cycle, both 15 year freedom from progression (FFP) and overall survival (OS) were superior in ECR patients compared with other patients continued on the same treatment (61% versus 37%; P < 0.001). A series of questions arise from these observations. Question 1: is the shortening of treatment detrimental? In a randomized Swedish trial, in one arm treatment was shortened in patients evaluated from the fifth cycle as ECR as compared with the standard eight cycles arm, 10 year cause-specific-survival (CSS) was 53 versus 69% [not significant (ns)]; 10 year OS 49% versus 58% (ns). Conversely, in the EORTC 20884 study, ECR patients given only six cycles did as well as patients entering CR later and, for this reason, given eight cycles (identical 6 year event-free survival 75%). Question 2: is early treatment adaptation in patients who failed to reach ER beneficial? In the French MDH 90 trial, 15% of children failed to reach ECR after four cycles; in these children only, anthracyclines plus alkylating agents were given and the dose of radiotherapy increased, improving the results observed in the previous trial. In the EORTC 20884 study, patients who failed to reach an ECR were switched earlier to involved field RT: their results matched those of ECR patients, at the difference of the previous trial. Question 3: is ER a predicting factor that can be used with any type of treatment? Probably not, based on the German Hodgkin's Lymphoma Study Group trial HD 9: ECR is highly dependent on specific interval from treatment start and on treatment intensity. DISCUSSION More general questions stem from these results. Question 4: is the definition of ER secured? With conventional imaging, the different methods for response assessment at end treatment also lead to different response rates; the assessment in the middle of treatment itself and the use of newer imaging techniques may further increase the variation. Indeed, question 5 is: is ER a concept based on any biology? Correlation to markers, 99mTc uptake, PET and hematological tolerance might help to pinpoint how and why ER represents a surrogate for final outcome. CONCLUSION ER is a surrogate for final outcome, reflecting both tumor burden and activity. This predictability may, and possibly should, impact on treatment.
Collapse
Affiliation(s)
- P Carde
- Department of Medicine, Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Carde P, Cavalli F, Diehl V, Franklin J. Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease? Hematol J 2002; 1:282-90. [PMID: 11920203 DOI: 10.1038/sj.thj.6200037] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/15/2000] [Accepted: 04/03/2000] [Indexed: 11/09/2022]
Affiliation(s)
- P Carde
- Institute Gustav-Roussy, Villejuif, France.
| | | | | | | |
Collapse
|
24
|
Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J, Glabbeke MV, Henry-Amar M, Carde P. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002; 38 Suppl 4:S107-13. [PMID: 11858975 DOI: 10.1016/s0959-8049(01)00446-4] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
From 1964 onwards, the EORTC Lymphoma Group has conducted seven consecutive randomised phase 3 trials on early stage Hodgkin's lymphoma aiming at increasing efficacy, while decreasing short- and long-term toxicity. Staging laparotomy is definitely abandoned and replaced by identification of prognostic subgroups based on pretreatment clinical characteristics. Event-free and overall survival significantly improved from about 50 and then 70%, in the early years, to over 80 and then 90% more recently. Radiotherapy fields have become more restricted, whereas chemotherapy has become standard. Longitudinal quality-of-life assessment has become an integral part of our studies. In advanced stages, overall outcome has improved as well with 6-year survival rates of over 80%. In aggressive types of NHL, the second generation chemotherapy schedule CHVmP-BV was superior to CHVmP. We could not show any advantage for intensification of upfront treatment with autologous stem cell transplantation.
Collapse
Affiliation(s)
- J Raemaekers
- Deptartment of Hematology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Girinsky T, Guillot-Vals D, Koscielny S, Cosset JM, Ganem G, Carde P, Monhonval M, Pereira R, Bosq J, Ribrag V, Vantelon JM, Munck JN. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 2001; 51:148-55. [PMID: 11516864 DOI: 10.1016/s0360-3016(01)01626-1] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
PURPOSE To determine the efficacy of small doses of radiation in patients with recurrent or refractory low-grade lymphoma masses. METHODS AND MATERIALS Patients with refractory or relapsing low-grade lymphoma masses. The two largest diameters of the tumor mass were measured, whenever possible, before and after treatment. A dose of 4 Gy of radiotherapy was delivered to tumor sites in 2 fractions. Patients were evaluated for response 1-4 months later and at regular follow-up visits. RESULTS Forty-eight patients with low-grade lymphomas according to the working formulation received low-dose radiotherapy between March 1987 and November 1998. Most patients had advanced disease at the time of radiation treatment, and 80% had received at least two chemotherapy regimens before treatment. The median interval between the initial diagnosis and radiotherapy was 2.7 years (range 0-22 years). Low-dose radiation was delivered to 135 tumor sites. Nodal and extranodal tumor sites represented 80% and 20% of masses, respectively. An objective response was obtained in 81% of the sites, with 57% attaining a complete remission. The 2-year actuarial freedom from local progression (FFLP) rate was 56% (95% CI, 46-66%). Tumor masses </=5 cm in diameter had a significantly higher 2-year FFLP rate than larger masses (51% vs. 27%). It is noteworthy that the 2-year FFLP rate for patients treated with less than 2 chemotherapy regimens before radiotherapy was significantly higher than the 2-year FFLP rate for more heavily treated patients (96% vs. 48%). The 2-year FFLP rates for extranodal tumor sites and nodal sites were not significantly different. The tumor size (< or =5 cm vs. > 5 cm), the number of chemotherapy regimens (0-1 vs. more), and age at time of radiation treatment (< or =65 years or > 65 years) were significant predictive parameters of response to treatment. CONCLUSIONS In this retrospective study, low-dose radiation proved efficient, with long-lasting effects in the majority of patients with recurrent or refractory low-grade lymphomas. This simple and nontoxic treatment should be investigated prospectively in patients with advanced disease and a low tumor burden not immediately warranting chemotherapy.
Collapse
Affiliation(s)
- T Girinsky
- Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA, Renschler MF. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001; 19:2074-83. [PMID: 11283141 DOI: 10.1200/jco.2001.19.7.2074] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Motexafin gadolinium is a magnetic resonance imaging (MRI)--detectable redox active drug that localizes selectively in tumor cells and enhances the effect of radiation therapy. This phase Ib/II trial of motexafin gadolinium, administered concurrently with 30 Gy in 10 fractions whole-brain radiation therapy (WBRT), was conducted to determine maximum-tolerated dose (MTD), dose-limiting toxicity, pharmacokinetics, and biolocalization in patients with brain metastases. Additional endpoints were radiologic response rate and survival. PATIENTS AND METHODS Motexafin gadolinium was administered before each radiation treatment in this open-label, multicenter, international trial. In phase Ib, drug dose was escalated until the MTD was exceeded. In phase II, drug was evaluated in a narrow dose range. RESULTS In phase Ib, the motexafin gadolinium dose was escalated in 39 patients (0.3 mg/kg to 8.4 mg/kg). In phase II, 22 patients received 5 mg/kg to 6.3 mg/kg motexafin gadolinium. Ten once-daily treatments were well tolerated. The MTD was 6.3 mg/kg, with dose-limiting reversible liver toxicity. Motexafin gadolinium's tumor selectivity was established using MRI. The radiologic response rate was 72% in phase II. Median survival was 4.7 months for all patients, 5.4 months for recursive partitioning analysis (RPA) class 2 patients, and 3.8 months for RPA class 3 patients. One-year actuarial survival for all patients was 25%. CONCLUSION Motexafin gadolinium was well tolerated at doses up to 6.3 mg/kg, was selectively accumulated in tumors, and, when combined with WBRT of 30 Gy in 10 fractions, was associated with a high radiologic response rate.
Collapse
Affiliation(s)
- P Carde
- Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Vantelon JM, Munck JN, Bourhis JH, Pico JL, Fadel C, Ulusakarya A, Carde P, Fenaux P, Ribrag V. Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy. Bone Marrow Transplant 2001; 27:531-6. [PMID: 11313688 DOI: 10.1038/sj.bmt.1702812] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2000] [Accepted: 12/10/2000] [Indexed: 11/09/2022]
Abstract
Ten patients with refractory (n = 8) or early relapsing (n = 2) aggressive non-Hodgkin's lymphoma were enrolled in a pilot study evaluating a high-dose sequential chemotherapy regimen with peripheral blood stem cell (PBSC) support. Five treatment phases were scheduled: phase I (cyclophosphamide + etoposide followed by lenograstim (G-CSF), and a PBSC harvest); phase II (cisplatinum + cytarabine + etoposide followed by lenograstim); phases III and IV (cyclophosphamide + cytarabine + etoposide followed by autologous PBSC infusion and lenograstim); and phase V (carmustine + cytarabine + etoposide + melphalan followed by autologous PBSC infusion and lenograstim). Ten, nine, eight, six and four of the 10 patients received one, two, three, four and five of the five scheduled phases of treatment, respectively. Four patients were withdrawn from the study due to progressive disease and two due to thrombotic microangiopathy (TM). Moreover, in the four patients who completed all treatment phases, an additional case of TM was seen. In all three patients with TM, laboratory studies showed evidence of Coombs negative hemolytic anemia, thrombocytopenia, renal dysfunction and in addition cardiac failure in two patients. TM may be a new dose-limiting toxicity of high-dose sequential chemotherapy followed by repeated PBSC transplantation.
Collapse
Affiliation(s)
- J M Vantelon
- Department of Medicine, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM, Musson H, Teodorovic I, Maes B, Carbone A, Carde P, Thomas J. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001; 93:22-30. [PMID: 11136838 DOI: 10.1093/jnci/93.1.22] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor. Consequently, the European Organization for Research and Treatment of Cancer Lymphoma Group designed a prospective randomized trial to investigate whether high-dose chemotherapy plus autologous bone marrow transplantation (ABMT) after standard combination chemotherapy improves long-term survival. METHODS Patients aged 15-65 years with aggressive NHL received three cycles of CHVmP/BV polychemotherapy (i.e., a combination of cyclophosphamide, doxorubicin, teniposide, and prednisone, with bleomycin and vincristine added at mid-cycle). After these three cycles, patients with a complete or partial remission and at that time no lymphoma involvement in the bone marrow were randomly assigned to the ABMT arm (a further three cycles of CHVmP/BV followed by BEAC [i.e., a combination of carmustine, etoposide, cytarabine, and cyclophosphamide] chemotherapy and ABMT) or to the control arm (five more cycles of CHVmP/BV). All statistical tests are two-sided. RESULTS From December 1990 through October 1998, 311 patients (median age = 44 years) were registered and received the first three cycles of CHVmP/BV, and 194 patients were randomly assigned to the treatment arms. Approximately 70% (140 patients) of these patients were of low or low-intermediate International Prognostic Index (IPI) risk. After a median follow-up of 53 months, an intention-to-treat analysis showed a time to disease progression and overall survival at 5 years of 61% (95% confidence interval [CI] = 51% to 72%) and 68% (95% CI = 57% to 79%), respectively, for the ABMT arm and 56% (95% CI = 45% to 67%) and 77% (95% CI = 67% to 86%), respectively, for the control arm. Differences between arms were not statistically significant. A subset analysis on IPI risk groups, although too small for reliable statistical analysis, yielded similar results. CONCLUSIONS Standard combination therapies remain the best choice for most patients with aggressive NHL. We recommend that patients with IPI low or low-intermediate risk not be subjected to high-dose chemotherapy and ABMT as a first-line therapy.
Collapse
Affiliation(s)
- H C Kluin-Nelemans
- Department of Hematology, Leiden University Medical Center, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
Mantle cell lymphomas are characterized by a male predominance with a range between 55 and 65 years (sex ratio M/F of 6.5). When the sex ratio of patients having mantle cell lymphoma was compared to that of each of the subtypes of non-Hodgkin's lymphomas, it was significantly higher in all cases except Burkitt's and lymphoblastic T-cell lymphomas. These observations suggest a possible relation between the chromosome X and mantle cell lymphomas which has to be explored.
Collapse
Affiliation(s)
- D Decaudin
- Department of Hematology, Institut Curie, Paris, France.
| | | | | |
Collapse
|
30
|
Carde P. Maladie de Hodgkin: pourquoi faut-il la radiothérapie dans les stades étendus III–IV ? Cancer Radiother 1999. [DOI: 10.1016/s1278-3218(00)88239-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler M. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 1999; 212:755-9. [PMID: 10478243 DOI: 10.1148/radiology.212.3.r99se10755] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
PURPOSE To evaluate magnetic resonance (MR) imaging results after administration of gadolinium texaphyrin, a tumor-selective radiation sensitizer that is detectable at MR imaging, and to determine an appropriate intravenous dose of gadolinium texaphyrin for repeated injections during radiation therapy, the dose-limiting toxicity of reiterated doses of gadolinium texaphyrin, the maximal tolerated dose, the biolocalization of gadolinium texaphyrin (as assessed at MR examinations), and the response to treatment. MATERIALS AND METHODS Ten daily intravenous injections of gadolinium texaphyrin, each followed by whole-brain radiation therapy (total of 10 fractions, 30 Gy), were administered to patients with brain metastases in a multicenter study. At the study institution, 11 patients underwent MR imaging before and after the first injection, after the 10th injection, and 8 weeks after entry into the study. RESULTS MR imaging revealed selective drug uptake in metastases, without enhancement of normal brain tissue. In 10 patients, tumor uptake was higher after the 10th injection than after the first injection, which indicated accumulation of gadolinium texaphyrin in metastases. One lesion was visible only after the 10th injection and not at the pretherapeutic MR examination with injection of conventional gadolinium-based contrast material. Response to treatment was defined as a reduction in the size of the metastases between the preinjection MR study and the last MR study; seven patients achieved partial remission with tumor regression exceeding 50% of the initial size, and four achieved a minor response with less than 50% tumor regression. CONCLUSION These preliminary results indicate that gadolinium texaphyrin is tumor selective and that brain metastases can be depicted at MR imaging long after the administration of gadolinium texaphyrin.
Collapse
Affiliation(s)
- J Viala
- Department of Radiology, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | |
Collapse
|
32
|
Abstract
The role of radiotherapy in limited stage Hodgkin's disease (HD) has been gradually changing in the past few decades, resulting in the almost complete disappearance of exclusive irradiation treatment. In reality, exclusive radiotherapy yielded satisfactory results in terms of long-term survival, but in 1999 it was becoming impossible not to take into account the late mortality rates observed in all large cohorts of HD patients. This increased mortality rate has been shown to be related to 1) cardiac toxicity of irradiation, and 2) secondary radiation-induced solid tumors. Thus, the search for efficient but less toxic new strategies can no longer be avoided. For clinically staged, limited HD, precisely defined according to specific prognostic factors, the association of chemotherapy and radiotherapy appears more and more as a standard, and with this therapeutic burden comes parallel efforts for its alleviation. The Previous Radiotherapy experience has shown that, after a chemotherapy-induced complete remission, irradiation of only the initially involved areas was enough. Ongoing trials are now exploring the possibility of a dose de-escalation, from the conventional 36 Gy to 20 Gy (as for children HD), and to maybe 0 Gy (no radiotherapy at all). In parallel, deescalation in the number of chemotherapy cycles is also being investigated. For unfavorable cases, the problem is slightly different, as a higher percentage of cases still appears to be refractory to treatment in this subgroup. Thus, while chemo-radiotherapy has clearly became the standard strategy, efforts are essentially being devoted to identify new--and hopefully more efficient--chemotherapy schemes. In Europe, most of these pending questions will be addressed in the recently initiated trials of the EORTC/GELA and of the GHSG (German Hodgkin Study Group), with the aim of offering to patients treatment which could be at least as efficient as the present schedules, and less toxic in the long term.
Collapse
|
33
|
Abstract
We investigated whether T-cell clonal expansion could be found in the blood of 14 untreated patients with B-cell lymphoproliferative disorders [5 B-chronic lymphocytic leukemia (CLL), 4 myelomas, 5 non-Hodgkin lymphoma (NHL)]. The putative presence of T-cell clonotypes was analyzed with a polymerase chain reaction-based method determining V-D-J junction size patterns in 24 T-cell receptor (TCR) V beta subfamilies. This high-resolution method, analyzing CDR3 sizes of TCR transcripts, was used in conjunction with cytometric analysis of the corresponding T-cell subpopulations with 18 TCR V beta-specific monoclonal antibody. We found multiple dominant T-cell clonotypes in the blood of most patients with B-CLL or myeloma as well of a patient with stage IV NHL. In some cases, T-cell clonal expansion was so dominant that the percentage of these clonal T-cell subpopulations in blood represented more than the mean +2 SD value determined in a series of healthy controls. We conclude that a systemic antigen-specific (i.e., leading to clonotypic expansion) immune reaction involving few TCR clonotypes is a hallmark of disseminated B-cell malignancies. The nature of the putative antigens recognized is not known presently. Nonetheless, such insights into the T-cell repertoire of these patients may help to reassess the potential of immunotherapeutic strategies in B-cell malignancies.
Collapse
MESH Headings
- Adult
- Aged
- Complementarity Determining Regions
- DNA/analysis
- Female
- Genes, T-Cell Receptor beta/genetics
- Humans
- Immunoglobulin alpha-Chains/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Lymphoma, Non-Hodgkin/immunology
- Male
- Middle Aged
- Multiple Myeloma/immunology
- Polymerase Chain Reaction
- Receptors, Antigen, T-Cell, alpha-beta/genetics
- Receptors, Antigen, T-Cell, alpha-beta/immunology
- T-Lymphocytes/immunology
Collapse
Affiliation(s)
- N Alatrakchi
- Laboratoire d'Immunologie Cellulaire, INSERM U3331, Villejuif, France
| | | | | | | | | | | |
Collapse
|
34
|
Carde P, Cosset JM. [Prognostic factors and treatment of localized Hodgkin's disease]. Rev Prat 1998; 48:1075-81. [PMID: 9781151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Cure is warranted in most cases of localized Hodgkin's disease, the more frequent ones. However, after 10 years of follow-up, early and late mortality of iatrogenic origin exceed casualties related to tumor progression. Reductions in irradiation doses and fields, as well as wiser chemotherapy choices attempt to circumvent these complications. Nevertheless, as long as the mechanism of disease propagation and the prognostic factors are not better defined, only pragmatic approaches are being tested. Large cooperative trials are therefore needed to improve the outcome.
Collapse
Affiliation(s)
- P Carde
- Institut Gustave-Roussy (Service de médecine C. Suzanne Axel), Villejuif
| | | |
Collapse
|
35
|
Ribrag V, Nasr F, Bouhris JH, Bosq J, Brault P, Girinsky T, Cosset JM, Munck JN, Corti C, Decaudin D, Pico JL, Hayat M, Carde P. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone Marrow Transplant 1998; 21:969-74. [PMID: 9632268 DOI: 10.1038/sj.bmt.1701202] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Forty-two patients with refractory (15 patients) or relapsed (27 patients) Hodgkin's disease (HD) were included in a prospective single center study evaluating the efficacy of a regimen VIP combining etoposide 75 mg/m2/day days 1-5, ifosfamide 1.2 g/m2/day days 1-5 and cisplatinum 20 mg/m2/day days 1-5, one course every 4 weeks as salvage therapy in patients with refractory or relapsed Hodgkin's disease, potentially eligible for high-dose chemotherapy with reinjection of hematopoietic stem cells (HSC). If patients were considered chemosensitive after two courses of VIP, high-dose chemotherapy followed by the reinjection of HSC was planned. After two courses of VIP, 67% achieved an objective response including 38% complete responses. Overall, 28 patients went on to high-dose therapy with reinjection of HSC, and 46% of grafted patients are in a sustained complete remission. When the overall patient population is considered, 33% are in complete remission (CR) with a median follow-up of 37 months. A CR of less than 12 months and refractory disease were associated with a poor survival. These results showed that the VIP regimen is effective in relapsed or refractory HD and allows high-dose therapy to be given in the case of most responding patients. However, results in patients with refractory disease or a first complete remission of less than 12 months need to be further improved.
Collapse
Affiliation(s)
- V Ribrag
- Service de Médecine C, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Carde P, Noordijk EM. Studying spreading pattern in Hodgkin's disease: is it relevant to modern cancer treatment? Radiother Oncol 1998; 47:3-5. [PMID: 9632286 DOI: 10.1016/s0167-8140(97)00216-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
37
|
Bogden AE, Moreau JP, Gamba-Vitalo C, Deschamps de Paillette E, Tubiana M, Frindel E, Carde P. Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSF. Int J Cancer 1998; 76:38-46. [PMID: 9533760 DOI: 10.1002/(sici)1097-0215(19980330)76:1<38::aid-ijc8>3.0.co;2-z] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The aim of our study was to investigate the protection afforded to the bone marrow by Goralatide (AcSDKP), an inhibitor of hemopoietic stem cell proliferation, when administered alone or in combination with a growth factor (granulocyte/macrophage colony-stimulating factor [GM-CSF]) during iterative cycles of Ara-C (cytarabine) treatment. In control mice receiving the inhibitor alone without Ara-C, the number of granulocytes was reduced during treatment, and a surge in number of peripheral blood cells was observed after its completion. Peripheral hematological responses were monitored during 3 consecutive cycles of Ara-C chemotherapy and the resultant nadir and recoveries. Analysis of variance of the treatment effects pooled over the 3 cycles showed that a treatment regimen in which the inhibitor was administered during the myelotoxic periods of chemotherapy confirmed the existence of a surge after completion of administration of the inhibitor and showed a significant protective effect. When the cycles of chemotherapy plus Goralatide were followed by GM-CSF, the recovery from leukopenic nadirs was accelerated and the white blood cells and granulocyte levels were markedly increased over those observed in control mice and in mice treated either with Goralatide alone or with GM-CSF alone. The differences were highly significant. A consistent and significant increase (p < 0.001) in platelet count was also noted in animals given Goralatide in conjunction with Ara-C or Ara-C + GM-CSF. After three treatment cycles, this response to the CSF was far better in mice treated by the inhibitor than when CSF was given alone, suggesting a protection of the stem cell pool.
Collapse
|
38
|
Decaudin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat AM, Bayle C, Carde P, Bendahmane B, Hayat M, Munck JN. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998; 16:579-83. [PMID: 9469344 DOI: 10.1200/jco.1998.16.2.579] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE The aim of this phase II trial was to assess the efficacy of fludarabine monophosphate in untreated and pretreated mantle-cell lymphomas (MCL). PATIENTS AND METHODS Fifteen patients with MCL were included in the study. In two cases, fludarabine was the first-line therapy, the second in four cases, the third in five cases, and the fourth in four cases. The diagnosis of MCL was based on the criteria of the European Lymphoma Task Force (ELTF), with morphologic, immunologic, and cytogenetic data. Patients were treated with intravenous fludarabine 25 mg/m2/d for 5 days every 4 weeks. RESULTS Toxicity of fludarabine was mild: World Health Organization (WHO) grade 3 and 4 granulocytopenia occurred in 15 of 56 assessable cycles (cy) (27%), there was no grade 3 or 4 thrombocytopenia, one grade 3 bacterial lung infection, and no treatment-related death. There were five partial responses (33%) but no complete response. The duration of these responses was short and ranged from 4 to 8 months. CONCLUSION These results suggest that fludarabine can be moderately effective in the treatment of MCL. Fludarabine appears to be far less effective than in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL). Therefore, fludarabine should be evaluated in association with other chemotherapeutic agents in MCL.
Collapse
Affiliation(s)
- D Decaudin
- Department of Medicine, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Massé A, Ramirez LH, Bindoula G, Grillon C, Wdzieczak-Bakala J, Raddassi K, Deschamps de Paillette E, Mencia-Huerta JM, Koscielny S, Potier P, Sainteny F, Carde P. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors. Blood 1998; 91:441-9. [PMID: 9427696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP or Goralatide), a physiological regulator of hematopoiesis, inhibits the entry into the S-phase of murine and human hematopoietic stem cells. It has been shown to reduce the damage to specific compartments in the bone marrow resulting from treatment with chemotherapeutic agents, ionizing radiations, hyperthermy, or phototherapy. The present study was performed to assess the therapeutic potential of AcSDKP in vivo in reducing both the toxicity and the hematopoietic damage induced by fractionated administration of doxorubicin (DOX), a widely used anticancer drug. Here we showed that AcSDKP could reduce DOX-induced mortality in mice and could protect particularly the long-term reconstituting cells (LTRCs) in addition to colony forming units-spleen, high proliferative potential colony-forming cells, and colony-forming units-granulocyte-macrophage (CFU-GM) from DOX toxicity. The protection against DOX-induced mortality in mice was improved when AcSDKP was administered for 3 days, at a dose of 2.4 micrograms/d, by continuous subcutaneous (SC) infusion or fractionated s.c. injections starting 48 hours before DOX treatment. Moreover, the recovery of the CFU-GM population in the AcSDKP-DOX-treated mice was optimized by the subsequent administration of granulocyte colony-stimulating factor (G-CSF). The coadministration of AcSDKP with DOX may improve its therapeutic index by reducing both acute hematotoxicity on late stem cells and progenitors and long-term toxicity on LTRCs. Optimization of these treatments combined with G-CSF may provide an additional approach to facilitate hematopoietic recovery after cancer chemotherapy.
Collapse
Affiliation(s)
- A Massé
- Institut Gustave Roussy, Villejuif, IPSEN-Biotech, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Timmerman B, Carde P, Koprowski C, Arwood D, Ford J, Mehta M, Tishler R, Larner J, Miller R, Koffler-Horovitz S, Hoth D, Renschler M. Phase IB/II trial of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) for patients with brain metastases: Final results. Int J Radiat Oncol Biol Phys 1998. [DOI: 10.1016/s0360-3016(98)80248-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
41
|
Kesserling C, Renschler M, Vanel D, Mathews V, Rosenthal D, Carde P, Timmerman B, Koprowski C, Arwood D, Ford J, Miller R, Mehta M. Selective uptake and retention of the radiation sensitizer gadolinium texaphyrin (Gd-Tex) in tumors demonstrated by MRI in phase I and II clinical trials. Int J Radiat Oncol Biol Phys 1998. [DOI: 10.1016/s0360-3016(98)80379-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, Raemaekers JM, van Hoof A, De Wolf-Peeters C, van Glabbeke M. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1998; 16:41-7. [PMID: 9440721 DOI: 10.1200/jco.1998.16.1.41] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
PURPOSE Interferon alfa has shown significant activity in patients with low-grade malignant non-Hodgkin's lymphoma (NHL). In 1985, we initiated a prospective randomized study in which the potential benefit of interferon alfa given as maintenance treatment was investigated after tumor load reduction was achieved with chemoradiotherapy in patients with advanced low-grade malignant non-Hodgkin's lymphoma. PATIENTS AND METHODS The study involved 347 patients with stage III or IV disease, 315 satisfying the eligibility criteria. All were treated with a regimen of cyclophosphamide, vincristine, and prednisone (CVP) given every 3 weeks for eight cycles. Thereafter, patients were eligible for iceberg irradiation. Finally, all patients were completely restaged, and responding and stable-disease patients were then randomized, 122 to interferon alfa-2a maintenance, 3 million U three times weekly for 1 year; and 120 to no further treatment. RESULTS Seventy-nine percent of the patients response to CVP, ie, 45% complete remissions (CR) and 34% partial remissions (PR). In the group of randomized patients, the response rate after CVP plus or minus radiotherapy was 90%. As compared with control patients, patients in the interferon (IFN) maintenance group had a tendency toward a prolonged time to progression (TTP) (median, 132 v 87 weeks; P = .054, adjusted for response to CVP). However, overall survival was similar in both groups. Interferon was well tolerated. The median dose of IFN actually received corresponded to 90% of the planned cumulative dose. The treatment had to be stopped because of toxicity in 16 patients (15% of the patients in whom IFN was started). CONCLUSION Interferon maintenance treatment in the phase of minimal residual disease of patients with advanced low-grade malignant NHL increased TTP at the borderline of statistical significance, without remarkable toxicity. However, overall survival was not influenced.
Collapse
Affiliation(s)
- A Hagenbeek
- The Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Decaudin D, Bosq J, Munck JN, Bayle C, Koscielny S, Boudjemaa S, Bennaceur A, Venuat AM, Naccache P, Bendahmane B, Ribrag V, Carde P, Pico JL, Hayat M. Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. Leuk Lymphoma 1997; 26:539-50. [PMID: 9389361 DOI: 10.3109/10428199709050890] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We reviewed 77 cases considered as lymphocytic lymphomas of intermediate differentiation or diffuse centrocytic lymphomas. Forty-five cases were diagnosed as mantle cell lymphoma (MCL). The architectural pattern was diffuse in 95%, 8 cases presented large blastoid cells and CD5 positivity was observed in 28/34 cases. Of 20 cases studied, 8 presented a t(11;14)(q13;q32). Patient characteristics were: median age 59 years, B symptoms in 38%, 87% stages III-IV, bone marrow involvement in 67% with peripheral leukemic cells in 24%. Forty-four patients were treated with chemotherapy and 7 received radiotherapy. The complete response (CR) rate was 58%. Of the 26 CR, 19 relapsed at a median of 15 months. Disease-free survival was 42% and overall survival was 73% at 3 years. In a univariate analysis, overall survival was related to liver and bone marrow involvement, the presence of peripheral lymphomatous cells and achieving a complete response.
Collapse
MESH Headings
- Adult
- Aged
- Female
- Follow-Up Studies
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Lymphoma, Non-Hodgkin/genetics
- Lymphoma, Non-Hodgkin/pathology
- Lymphoma, Non-Hodgkin/therapy
- Male
- Middle Aged
- Prognosis
Collapse
Affiliation(s)
- D Decaudin
- Department of Medicine, Institute Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Nasr F, Macintyre E, Venuat AM, Bayle C, Carde P, Ribrag V. Translocation t(4;11)(q21;q23) and MLL gene rearrangement in acute lymphoblastic leukemia secondary to anti topoisomerase II anticancer agents. Leuk Lymphoma 1997; 25:399-401. [PMID: 9168451 DOI: 10.3109/10428199709114180] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Secondary therapy-related, acute lymphoblastic leukemia (S-ALL) is less common than its myeloblastic counterpart. S-ALL with MLL gene rearrangements have only been reported on six previous occasions. Only three of these had t(4;11)(q21;23) S-ALL with MLL-AF4 fusion transcript has only been reported in one earlier case. In this report a rare case of S-ALL with MLL-AF4 transcript is described in a 36 year old woman treated for breast carcinoma with chemotherapy which included the topoisomerase II inhibitor, VP-16. The precise incidence of MLL gene rearrangement in S-ALL still remains to be clarified.
Collapse
Affiliation(s)
- F Nasr
- Service de Médecine C., Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | |
Collapse
|
45
|
Carde P. [Hodgkin's disease trials conducted by the European Organization of Research and Treatment of Cancer (EORTC): their impact on the progress of cancerology]. Bull Acad Natl Med 1997; 181:139-57; discussion 157-62. [PMID: 9162510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Hodgkin's disease is a rare event that allowed key progress in the field of Oncology. Starting 1964 the EORTC has conducted a series of comprehensive controlled trials of outmost importance from the time of the first cures achieved with extended field radiotherapy until the observation that dose-response relationships could occur both for tumor control and for the incidence of second leukemia, cardiac, and pulmonary toxicities. Each of these steps is depicted in some detail. The contributions of the EORTC include in particular the first demonstration ever of the positive impact of an adjuvant chemotherapy on the freedom from progression and overall survival of a cancer (1964-1972), the identification of prognostic factors usable to adapt the aggressivity of treatment to patient's risks and the role of excess mortality from iatrogenic origin. Directions are indicated to insure a continuous progress to the Oncology field through additional Hodgkin's disease studies.
Collapse
Affiliation(s)
- P Carde
- Institut Gustave Roussy (Service de médecine C--Unité Suzanne Axel), Villejuif
| |
Collapse
|
46
|
Meerwaldt J, Carde P, Somers R, Thomas J, Kluin-Nelemans J, Bron D, Noordijk E, Cosset J, Bijnens L, Teodorovic I, Hagenbeek A. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. Ann Oncol 1997. [DOI: 10.1093/annonc/8.suppl_1.s67] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
Raemaekers J, Burgers M, Henry-Amar M, Pinna A, Mandard A, Monfardini S, Hagenbeek A, Breed W, Carde P, Vovk M, van Hoof A, Thomas J, Noordijk E. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. Ann Oncol 1997; 8 Suppl 1:111-4. [PMID: 9187443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Failure to reach complete remission (CR) with chemotherapy in advanced stages of Hodgkin's disease is considered a poor prognostic factor for progression-free and overall survival. The role of radiotherapy after chemotherapy-induced remission is controversial. PATIENTS AND METHODS In 1989, the EORTC/GPMC started a randomized phase III trial on involved-field RT (IF-RT) after MOPP/ABV hybrid-induced remission in patients with stage III/IV Hodgkin's disease. In this ongoing trial, patients in CR after chemotherapy are randomized between IF-RT and no further treatment. Patients in partial remission (PR) all receive IF-RT. Patients, age 15-70 years, with previously untreated stage III/IV Hodgkin's disease are eligible. The randomized treatment arms are still blinded. The interim analysis of May 1996 focuses on the outcome of patients in chemotherapy-induced PR. RESULTS A total of 405 of 493 registered patients were evaluable for response to chemotherapy. Fifty-nine percent of patients attained a CR, 37% a PR, and only 4% failed to respond. The IF-RT was actually given to 90% of the PR patients. After a median follow-up of 43 months, the five year progression-free and overall survival for patients in PR was 75% and 87%, respectively. CONCLUSION IF-RT after MOPP/ABV-induced partial remission in stage III/IV Hodgkin's disease produces excellent failure-free and overall survival. Early intensification of treatment of this group of patients is not indicated.
Collapse
|
48
|
Meerwaldt JH, Carde P, Somers R, Thomas J, Kluin-Nelemans JC, Bron D, Noordijk EM, Cosset JM, Bijnens L, Teodorovic I, Hagenbeek A. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group. Ann Oncol 1997; 8 Suppl 1:67-70. [PMID: 9187434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
CHOP has been and still is regarded by many as the 'standard' treatment of advanced non-Hodgkin's lymphoma. In 1980 the EORTC Lymphoma Cooperative Group started a study to evaluate the addition of vincristine and bleomycin to its standard four-drug combination chemotherapy, CHVmP (cyclophosphamide, hydroxorubicin, Vm-26, prednisone). Eligible patients were stage III or IV, intermediate- to high-grade non-Hodgkin's lymphoma (Working Formulation E-I). One-hundred-eighty-nine patients were entered, of whom 140 were eligible and evaluable. A previous report showed an improved response rate and failure-free survival (FFS) and overall survival for the combination CHVmP-VB. At ten years, the outcome still favors the addition of vincristine and bleomycin. The FFS was 34% vs. 23% and the overall survival 34% vs 22%. This difference was mainly due to a difference in CR rate (74% vs. 49%), Relapse-free survival for patients reaching a CR was the same in both arms. When the patients were grouped according to the International Prognostic Factor Index, no statistically significant difference could be observed in favor of one treatment within either group. This trial clearly demonstrates the benefit gained by the addition of vincristine and bleomycin to 'standard' chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma.
Collapse
|
49
|
Meerwaldt JH, Carde P, Somers R, Thomas J, Kluin-nelemans JC, Bron D, Noordijk EM, Cosset JM, Bijnens L, Teodorovic I, Hagenbeek A. Ann Oncol 1997; 8:67-70. [DOI: 10.1023/a:1008210102316] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Raemaekers J, Burgers M, Henry-Amar M, Pinna A, Mandard A, Monfardini S, Hagenbeek A, Breed W, Carde P, Vovk M, van Hoof A, Thomas J, Noordijk E. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial. Ann Oncol 1997. [DOI: 10.1093/annonc/8.suppl_1.s111] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|